ARTICLE | Clinical News
Durezol regulatory update
January 30, 2012 8:00 AM UTC
Novartis disclosed in its 4Q11 earnings that it submitted an NDA to FDA for Durezol difluprednate for uveitis. The topical ophthalmic emulsion containing difluprednate is marketed to treat inflammatio...